A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs ABBV-321 (Primary)
- Indications Bladder cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 05 Sep 2019 Planned End Date changed from 29 Aug 2023 to 4 Sep 2025.
- 05 Sep 2019 Planned primary completion date changed from 31 Aug 2021 to 7 Mar 2024.
- 01 May 2019 Planned primary completion date changed from 1 Sep 2019 to 31 Aug 2021.